Abstract:T cells play a critical role in allograft rejection. T-cell activation requires antigen recognition by the T-cell receptor (TCR)/CD3 complex and costimulation of accessory receptors. Non-FcR-binding anti-CD3ε antibodies (Abs) produce immunosuppression without the toxicity associated with Fc-dependent activation (1). Non-FcR-binding anti-CD3ε Abs may induce T-cell anergy, skew the T-cell repertoire toward the Th2 phenotype, modulate the TCR, and block antigen recognition (1). We have found that a critical mechanism of immunosuppression by non-FcR-binding anti-CD3ε Abs is the induction of apoptosis in antigen-activated T cells (2). Among the costimulatory receptors on T cells, CD28 has a pivotal role in the initiation and maintenance of T-cell responses. In various transplant models, inhibition of CD28:B7 interactions by CTLA4-Ig resulted in immunosuppression (3). However, treatment with anti-CD28 Abs was more effective than CTLA4-Ig in the prevention of graft-versus-host disease in mice (4). Therefore, selective targeting of CD28 may be a better approach to achieve transplantation tolerance than blocking B7 molecules, the ligands for both CD28 and CTLA4, as CTLA4 is inhibitory for T-cell activation. Here we tested the hypothesis that combined treatment with non-FcR-binding anti-CD3ε plus anti-CD28 Abs leads to transplantation tolerance by affecting independent and complementary pathways of T cell activation. The experiments were performed in the context of a strong allogeneic MHC stimulation by transplanting skin grafts from BALB/c (H2d) onto C57BL/6 (H2b) mice. Recipients were treated with control Ab, anti-CD28 alone, non-FcR-binding anti-CD3ε alone, or anti-CD3ε plus anti-CD28. As shown in Figure 1A, treatment with anti-CD3 significantly prolonged graft survival compared to control or anti-CD28 treatment (P <0.0001, P <0.0001), whereas anti-CD28 by itself was modestly effective (P =0.002). The combination of anti-CD3ε plus anti-CD28 Abs was significantly more effective than either Ab alone (P =0.002, and P <0.0001), but transplantation tolerance did not develop. We suspected that failure to achieve graft tolerance could result from non-tolerant T cells developing from the thymus after stopping treatment. These T cells could recognize alloantigens and reject the skin graft. To test this hypothesis, we utilized thymectomized C57BL/6 mice as recipients. Treatment with anti-CD3ε plus anti-CD28 Abs significantly prolonged graft survival compared to control Ab (Fig. 1B), but the magnitude of the effect was not significantly different in normal or thymectomized recipients (P =0.5). Figure 1: Prolongation of murine skin allograft survival. Normal (A) or thymectomized (B) C57BL/6 mice were transplanted with full-thickness skin grafts from BALB/c donors. Recipients were intraperitoneally injected with the reagents indicated once every other day for a total of eight doses. The dose of anti-CD3ε and anti-CD28 Abs were 80 and 100 μg/mouse, respectively. The control Ab used was normal hamster IgG.We conclude that anti-CD3 and anti-CD28 Abs have additive immunosuppressive effects, but their combination does not induce tolerance to skin transplants. The failure of inducing transplantation tolerance with this treatment is not caused by the emergence of non-tolerant T cells from the host thymus, but may result from incomplete depletion of alloreactive T cells, lack of inducing T-cell unresponsiveness, and/or lack of generating regulatory T cells. Xue-Zhong Yu1 Yoshio Nitta2,3 Sasha J. Bidwell1 Claudio Anasetti1,4

Specific Tolerance Induction of Allo-Kb-skin Grafts by FK506 in the CD8-depleted H-2k Recipients Required Low Amounts of Kb-antigen

Efficacy of Ctla4-Ig in Preventing Acute Rejection of Fully Allogeneic Heart Allografts in Sensitized Recipients

Induction of donor-specific tolerance to skin graft by intrathymic inoculation of allogeneic histocompatibility antigen from C57BL/6 mice

Donor Specific Tolerance for MHC Mis-Matched Murine Skin Allograft Induced by Donor Bone Marrow Transplantation with Precondition of High Dose Immunosuppressants

ADDITIVE EFFECTS OF ANTI-CD3 AND ANTI-CD28 ON PROLONGATION OF ALLOGENEIC SKINGRAFT SURVIVAL

Short-term Pharmacological Inhibition of MyD88 Homodimerization by a Novel Inhibitor Promotes Robust Allograft Tolerance in Mouse Cardiac and Skin Transplantation.

Effect and Mechanisms of Transplantation Tolerance Induced by Donor Natural Killer T Cells(NKT) Infused Intravenously

Cardiac Allograft Tolerance Induced by Isogeneic CD4+CD25+ Regulatory T Cells.

A Given Number of Effector T Cells Can Only Destroy a Limited Number of Target Cells in Graft Rejection

Anti-γc and Anti-Il-2rβ Mabs Inhibit Donor-Antigen Reactive T Cells Proliferation and Induce H-Y Skin Graft Acceptance in Murine Model

Enhanced allogeneic skin-graft survival using sCD95L, sCD152, interleukin-10 and transforming growth factor-β in combination, and comparison with ciclosporin

EXPERIMENTAL STUDY ON INDUCTION OF SKIN ALLOGRAFT TOLERANCE IN MICE BY HEAT SHOCK PROTEIN 60

Early stage mechanism of the specific NF-κB inhibition induced cardiac allograft tolerance

B Cells Assist Allograft Rejection in the Deficiency of Protein Kinase C-Theta

BLOCK THE COMMON Γ CHAIN OF CYTOKINE RECEPTORS INDUCES PERMANENT ALLOGRAFT TOLERANCE

[Experimental Study of Immunological Tolerance Induced by Cytotoxic T Lymphocyte-Associated Antigen 4 Immunoglobulin in Fresh Bone Allografts].

Improvement of Transplantation Tolerance of Skin Allograft by Infusion of Donor Bone Marrow Cells and Its Mechanism

Interleukin-2 and Interferon-Gamma Double Knockout Mice Reject Heterotopic Cardiac Allografts.

Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance.

Impact of Donor MHC Class I or Class II Antigen Deficiency on First‐ and Second‐set Rejection of Mouse Heart or Liver Allografts

Antigen-specific killer polylactic-co-glycolic acid (PLGA) microspheres can prolong alloskin graft survival in a murine model.